Specifications include, but are not limited to: 1. Assess “business” opportunities for expanding the Molecular Cellular Therapy (MCT) activities and production and necessary steps to create the University’s vision of a Cell, Gene and Immunotherapy. The successful vendor will consider findings from an internal space utilization review, described below, to help the University assess whether MCT capital expansion is warranted. Develop high-level business plan to begin to test feasibility including suggestion of models (UM owned, UM subsidiary, JV, etc.) including necessary attributes to attract industry partners. It will also assess any complementary scientific and faculty issues within the vision for a Cell, Gene and Immnotherapy institute. 2. Outline the requirements for the development of a vector production facility to serve the needs of U of M investigators and potentially serve as a resource to other institutions and industry. Capabilities of this new facility should include viral vector development (e.g., AAV, lenti virus); non-viral vector development, and viral integration site analytics.